[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
This didactic paper reviews the different receptors families, the principal characteristics of the dopaminergic and serotoninergic receptors and their role in the aetiology and pathophysiology of schizophrenia. The current knowledge on interactions between serotoninergic and dopaminergic systems is also summarized. The theoretical and potential interests of these interactions in alleviating neuroleptic-induced extrapyramidal symptoms and improving negative signs in schizophrenia are also examined.
Guise
S
S
Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques et Laboratoire de Pharmacologie Clinique, Hôpital de la Timone, Marseille.
Soubrouillard
C
C
Blin
O
O
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D006801:Humans; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists